Mesenchymal stem cells might be used to induce tolerance in heart transplantation
Mesenchymal stem cells might be used to induce tolerance in heart transplantation
复制标题
间充质干细胞可用于诱导心脏移植的耐受性
DOI：
10.1016/j.mehy.2007.08.010
复制
发表时间：
2008-01-01
影响因子：
4.7
通讯作者：
Yi, Dinghua
中科院分区：
文献类型：
--
作者：
Zhou, Heping;Jin, Zhenxiao;Yi, Dinghua
心脏移植是终末期心脏病的最后治疗选择，但免疫抑制剂的副作用和终生免疫抑制带来的并发症仍然是不可避免的。间充质干细胞(MSC)是一种成体多能细胞，不仅能分化为心肌细胞，还能维持一定的免疫调节功能。有报道称，MSCs在体外和体内都能抑制同种异体反应性的CD4(+)T细胞，这是导致移植物血管进行性狭窄的慢性排斥反应的主要原因。我们的假设是，MSC可以逃避同种异体反应细胞的识别，并在心脏移植后与T细胞、树突状细胞等重要免疫细胞相互作用，诱导Th1/Th2平衡中的细胞因子谱向抗炎表型Th2转变。然后可能会诱导出耐受性。也可以想象，在特定的微环境中，MSCs可能向心肌细胞分化。需要进一步的工作来验证MSCs是否可以保护心脏移植物免受慢性排斥反应，以及它是否有可能被用作经典免疫抑制剂的替代品。(C)2007爱思唯尔有限公司。保留所有权利。
Heart transplantation is the last treatment selection for end-stage heart diseases, but the side-effects of immunosuppressive agents and morbidity brought by lifelong immunosuppression still remains unavoidable. Mesenchymal stem cell (MSC) is one kind of adult pluripotent cell that not only can differentiate into cardiomyocytes but also maintain some unique immunomodulatory function. There were reports that MSCs could both in vitro and in vivo suppress alloreactive CD4(+) T cell which is mainly responsible for chronic rejection that leads to progressive graft vascular stenosis. We based our hypothesis on that MSC could escape recognition of alloreactive cells and would interact with important immune cells such as T cells, dendritic cells after cardiac transplantation to induce a cytokine profile shift in the Th1/Th2 balance toward the anti-inflammatory phenotype Th2. And then tolerance may be induced. Also it is conceivable that MSCs may differentiate toward cardiomyocyte in the specific microenvironment. Further work are necessary to verify if MSCs can protect heart graft from chronic rejection and its potential to be used as substitutes for classic immunosuppressants. (c) 2007 Elsevier Ltd. All rights reserved.